Wayne Shaw

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

26h-index11.6kcitations48works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(38), Pancreatic function and diabetes(21), Diabetes Management and Research(14), Heart Failure Treatment and Management(8), Bipolar Disorder and Treatment(7)

Publications48 total

Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes
Annals of Internal Medicine·2025· 2 cited
Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events
Journal of Cardiac Failure·2024· 4 cited
Fasting substrate concentrations predict cardiovascular outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
2022Open Access
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Diabetes Care·2022· 16 citedOpen Access
Fasting substrate concentrations predict cardiovascular outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
2022Open Access
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
Journal of the American College of Cardiology·2022· 69 citedOpen Access
Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial
Cardiovascular Research·2021· 19 citedOpen Access
Insulin-like Growth Factor Binding Protein-7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
2020Open Access
Insulin-like Growth Factor Binding Protein-7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
2020· 1 citedOpen Access
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
Diabetes Care·2020· 27 citedOpen Access
Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
Journal of the American College of Cardiology·2020· 94 citedOpen Access
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
International Journal of Cardiology·2020· 35 citedOpen Access
1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS)
Diabetes·2020
139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS
Diabetes·2020
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Diabetes Obesity and Metabolism·2019· 26 citedOpen Access
Author response for "Clinical outcomes with canagliflozin according to baseline body mass index: results from &lt;i&gt;post hoc&lt;/i&gt; analyses of the CANVAS Program"
2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JACC Heart Failure·2019· 137 citedOpen Access
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus
Circulation·2019· 159 citedOpen Access
EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM
Journal of the American College of Cardiology·2019· 1 citedOpen Access
Canagliflozin and Stroke in Type 2 Diabetes Mellitus
Stroke·2018· 73 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Kenneth W. Mahaffey(31), Bruce Neal(27), Vlado Perkovic(22), Dick de Zeeuw(19), David R. Matthews(18), Mehul Desai(15), Greg Fulcher(14), Michael K. Hansen(10), Gemma A. Figtree(9), Gary Meininger(9), Frank Vercruysse(7), Ngozi Erondu(6), Shahnaz Shahinfar(6), James L. Januzzi(6), Naveed Sattar(6), Jialin Xu(5), Javed Butler(5), Norman Rosenthal(5), Terrance D. Barrett(4), Karin Rådholm(4)